Results 11 to 20 of about 6,565 (223)

The Cost Effectiveness of Psychological and Pharmacological Interventions for Social Anxiety Disorder: A Model-Based Economic Analysis. [PDF]

PLoS ONE, 2015
BackgroundSocial anxiety disorder is one of the most persistent and common anxiety disorders. Individually delivered psychological therapies are the most effective treatment options for adults with social anxiety disorder, but they are associated with ...
Ifigeneia Mavranezouli, Evan Mayo-Wilson, Sofia Dias, Kayleigh Kew, David M Clark, A E Ades, Stephen Pilling   +6 more
doaj   +11 more sources

Phenelzine treatment increases transcription factor AP-2 levels in rat brain [PDF]

, 2003
Mattias Damberg, Cecilia Berggård, Lars Oreland   +2 more
openalex   +3 more sources

Medicines for Anxiety: A Hundred Years of Tranquillity and More to Come? [PDF]

Hum Psychopharmacol
Human Psychopharmacology: Clinical and Experimental, Volume 41, Issue 2, March 2026.
Nutt D.
europepmc   +2 more sources

The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. [PDF]

Pharmacol Res Perspect
Distinct mechanisms of viability decreasing actions of selegiline in androgen‐insensitive PC3 and sensitive 22Rv1 PAC cell lines. MAO‐B inhibition in the mitochondrial membrane of PC3 cells leads to the upregulation of the BAX and downregulation of FOX and GLUT1 which potentially results in reduced glucose uptake and apoptosis induction.
Steib A, Pohóczky K, Tóth N, Kormos V, Kun J, Kálai T, Mangel L, Mátyus P, Helyes Z.   +8 more
europepmc   +2 more sources

Correction to "The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents". [PDF]

Pharmacol Res Perspect
Pharmacology Research &Perspectives, Volume 13, Issue 6, December 2025.
europepmc   +2 more sources

Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects

Frontiers in Pharmacology, 2022
MAOIs, a well-established class of antidepressant that operate through the inhibition of monoamine oxidase to increase available serotonin, have recently been identified as a surprisingly effective candidate for the circumvention of tumor-induced immune ...
James Brown, Zhe Li, Xi Wang, Yu Jeong Kim, Yu-Chen Wang, Yanning Zuo, Yanning Zuo, Weizhe Hong, Weizhe Hong, Pin Wang, Bo Li, Lili Yang, Lili Yang, Lili Yang, Lili Yang   +14 more
doaj   +1 more source

Evolution of ideas about the risk of tyramine syndrome developing during therapy with irreversible non-selective monoamine oxidase inhibitors (to the 70th anniversary of the first use of this group of antidepressants)

Неврология, нейропсихиатрия, психосоматика, 2022
We describe the history of studying of the problem of tyramine syndrome during the treatment with antidepressants, irreversible non-selective monoamine oxidase inhibitors. Data on clinical observations are presented.
D. S. Danilov, M. Yu. Brovko
doaj   +1 more source

The History of Irreversible Non-Selective MAOI Antidepressants in Russia (for their 70th Anniversary)

Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2023
The history of irreversible non-selective MAOI antidepressants in the USSR and Russia is systemized. The history of representatives’ appearance is described. The history of the study of pharmacological effects is highlighted.
D. S. Danilov
doaj   +1 more source

Monoamine oxidase inhibitors and neuroprotective mechanisms

Psychiatry and Clinical Psychopharmacology, 2021
There has been a resurgence of interest in recent years in monoamine oxidase inhibitors, primarily because of the demonstrated neuroprotective and/ or neurorescue properties of several of these drugs in a variety of toxic situations in vivo and in vitro.
Glen Baker, Dmitriy Matveychuk, Erin M. MacKenzie, Serdar Dursun, Darrell D. Mousseau   +4 more
doaj   +1 more source

National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010-2023. [PDF]

Hum Psychopharmacol
ABSTRACT Introduction We describe prescribing of anxiolytics/hypnotics/antidepressants at an all‐England level between 2010 and 2023, taking account of the influence of the COVID‐19 pandemic‐period. Methods All Primary Care Prescribing data for England for anxiolytics/hypnotics/antidepressant agents taken as tablets or capsules from 1 January 2010 to ...
Stedman M, Davies M, Levy JW, Ingram J, Taylor D, Heald A.   +5 more
europepmc   +2 more sources